Spi-1005 Ebselen
Ototoxicity
Sound Pharmaceuticals, IncorporatedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Ototoxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
D-thioctic acid US Department of Veterans Affairs | Phase 2/3 | B |
Sodium Thiosulfate Children's Oncology Group | Phase 3 | B |
Cholesterol Suspension University of Colorado, Denver | Phase 2 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →